Compare Axon Enterprise Inc (AXON) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Sanofi SA — how do they compare? Axon Enterprise Inc trades at $545 (market cap $44.11B), while Sanofi SA trades at $43.57 (market cap $102.91B). The key difference: Sanofi SA is far larger — about 2.3× Axon Enterprise Inc's market cap, and Sanofi SA pays a 5.6% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | SNY | |
|---|---|---|
Market Cap | $44.11B | $102.91B |
Sector | Technology | Health |
52-Week High | $870.97 | $52.34 |
52-Week Low | $345.94 | $41.33 |
Enterprise Value | $45.20B | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $547.03, down 3.32% on the day, with strong analyst support (81% buy ratings) and a consensus price target of $648.67. The stock shows bullish technical signals with support at $539 and resistance at $553. Recent earnings have been mixed with Q3 2025 missing estimates but Q4 2025 and Q1 2026 beating expectations. Revenue growth remains solid with 2026 projections at $3.0B and net profit margin improving to 6.9%.
Axon presents growth potential driven by strong demand for connected devices and software services, though elevated valuation ratios (P/E 220.67) pose risk. Positive sentiment stems from recent upgrades and institutional interest, including notable insider buying. Key risks include execution challenges and competitive pressures in the law enforcement technology sector.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
